Latest Boardroom Shifts News

Pacgold Limited reports promising high-grade gold anomalies from a major aircore drilling campaign at its Alice River Gold Project, alongside strategic board appointments and a successful Share Purchase Plan to fuel further exploration.

Southern Cross Gold Consolidated Ltd has completed its acquisition of Southern Cross Gold Ltd, issuing over 125 million shares and announcing key board changes. The move positions the company to advance the high-potential Sunday Creek Gold-Antimony Project amid a strengthened leadership team.

I Synergy Group Limited has reshaped its board with the resignation of Joshua Hunt, the appointment of Jiayi Yu as Non-Executive Director, and the promotion of Heng Jee Meng to Managing Director, signaling a renewed focus on shareholder value.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.

SomnoMed reports a robust 19.8% revenue increase in Q2 FY25 and updates its full-year guidance, reflecting strong demand and operational improvements amid ongoing production enhancements.

IPB Petroleum has appointed a new chairman and is intensifying efforts to secure funding for drilling its key Browse Basin assets, while maintaining a strong cash position and exploring new project opportunities.

Tower Limited has appointed CFO Paul Johnston as interim CEO following Blair Turnbull's resignation, with Deputy CFO Angus Shelton stepping in as interim CFO pending regulatory approval.

Mayfield Childcare is nearing the appointment of a new CEO while enacting significant board changes, including the elevation of Lubna Matta to Executive Director and Roseanne Healy to Chair.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

The Calmer Co. International Limited has reported a remarkable surge in sales and cash receipts for the first half of FY25, exceeding the entire FY24 sales. Alongside a strategic CEO transition and factory upgrade, the company is sharpening its focus on profitable growth and cost control.

Emyria Limited announces key leadership shifts with Greg Hutchinson stepping up as Executive Chairman and Dr. Michael Winlo transitioning to Chief Scientific Officer, aiming to scale innovative mental health therapies amid growing demand.

Mighty Kingdom Ltd has appointed Dylan Miklashek as Interim CEO and Duncan Gordon as Non-Executive Chair, signaling a fresh leadership approach amid a company restructuring.